• All about Allergens
  • 250K HP 2017
  • AAP Epi update 2017
  • AIFA registered charity
  • Information for health professionals

  • EpiPen® Jr and EpiPen® supply update
    November 14, 2017:  Further to last week’s communications regarding EpiPen® Jr supply constraints, the following is updated information regarding both EpiPen® Jr and EpiPen® supply. EpiPen® 300mcg adrenaline (epinephrine) autoinjector: Whilst most Australian pharmacies should currently have a...
  • Novalac Allergy Infant Formula Temporary Shortage
    November 14, 2017:  Bayer Australia Ltd (Bayer) has advised that they are experiencing a temporary shortage of Novalac Allergy rice protein based infant formula. This has resulted in very limited supply in pharmacies throughout Australia.  Bayer is working to increase the supply of ...
  • Supply of EpiPen® Jr with 30 November 2017 expiry during temporary shortage
    November 8, 2017:  Mylan Australia is experiencing a temporary shortage of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors. This supply disruption is due to an unforeseen delay in supply from the overseas manufacturer. In the meantime, to minimise the impact on patient care, Mylan has...
  • AusPollen App questionnaire
    October 20, 2017:  Auspollen invites people with hay fever (allergic rhinitis) and/or asthma that is made worse by allergens in the air, to evaluate free local AusPollen Apps.  The Apps provide daily levels of pollen in the air and can be accessed on the AusPollen website www.pollenforec...
  • ASCIA 2017 Conference Report
    September 19, 2017:   The 28th ASCIA Annual Conference was held in Auckland, New Zealand at the Viaduct Events Centre from Wednesday 13th to Friday 15th September 2017. This conference was a great success, with more than 550 registrations, an outstanding program, an interactive confe...
  • Food and Drug Administration (FDA) letter regarding EpiPen® adrenaline (epinephrine) autoinjectors
    September 9, 2017:  ASCIA has been alerted to a letter released by the FDA in the USA, regarding an investigation into the Mylan recall of EpiPen® devices earlier this year. To date, ASCIA has not received any correspondence regarding EpiPen®s failing to be discharged in an emergency situation...
  • ASCIA website update - Locate a Specialist
    September 5, 2017:  The ASCIA website listings for Allergy and Clinical Immunology Services in Australia and New Zealand have been significantly updated, to provide additional information in a more mobile/tablet responsive format.  The updated lists of Full (Ordinary) ASCIA members workin...
  • New ASCIA Allergic Rhinitis Clinical Update released in National Asthma Week 2017
    September 4, 2017:  To coincide with National Asthma Week (1-7 September 2017) and the start of Spring, the new ASCIA Allergic Rhinitis Clinical Update for health professionals has been released.  This document complements ASCIA allergic rhinitis e-training courses for health professional...
  • ASCIA Allergic Rhinitis treatment plan now includes thunderstorm asthma information
    August 29, 2017:  The ASCIA Treatment Plan for Allergic Rhinitis has been significantly updated.  The main changes (versus the 2015 version) are the inclusion of: Information about thunderstorm asthma A note about the importance of using INCS sprays correctly The TGA change in recom...
  • Food allergen challenges - benefits, risks and precautions
    August 4, 2017:  Food allergy occurs in around 1 in 20 children and in about 2 in 100 adults. The severity of allergic reactions can be unpredictable, ranging from mild through to severe allergic reactions (anaphylaxis).  While extremely uncommon, deaths due to food allergy have occurred ...
ASCIA is a WAO member society

ASCIA is a WAO member society
Follow ASCIA

ASCIA on facebookASCIA on TwitterASCIA on YouTube

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.


This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health

Verify here.